US Patent Issued to TOAGOSEI on April 29 for "Amino acid sequence derived from S protein of SARS-CoV2 for generating an anti-SARS-CoV-2 antibody" (Japanese Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,285,476, issued on April 29, was assigned to TOAGOSEI Co. LTD. (Tokyo).

"Amino acid sequence derived from S protein of SARS-CoV2 for generating an anti-SARS-CoV-2 antibody" was invented by Nahoko Baileykobayashi (Tsukuba, Japan) and Tetsuhiko Yoshida (Tsukuba, Japan).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides a synthetic peptide containing an amino acid sequence that can be used to produce antibodies against proteins derived from a new coronavirus (SARS-CoV-2). The synthetic peptide provided herein is recognized as an antigen relative to at least one mammal, contains an amino acid sequence which is LNESLIDLQELGKYEQYIKWP...